Community Pharmacist Intervention to Enhance Adherence in Cardiovascular Drug Initiators (PHARM-ADHERE)
The goal of this clinical trial is to evaluate a community pharmacist intervention aimed at improving medication adherence in patients starting newly prescribed medication for cardiovascular disease prevention. The main questions it aims to answer are:
- Does this community pharmacist intervention improve medication adherence?
- Which patients benefit the most from the intervention?
- How do patients experience the start-up of newly prescribed medication (which questions do they have and do they experience side effects?)?
- How do patients and pharmacists experience the intervention?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Els Mehuys
- Phone Number: +32478509830
- Email: els.mehuys@ugent.be
Study Contact Backup
- Name: Koen Boussery
- Phone Number: +3292648043
- Email: koen.boussery@ugent.be
Study Locations
-
-
-
Ghent, Belgium
- Recruiting
- Pharmaceutical Care Unit (Ghent University)
-
Contact:
- Els Mehuys
- Phone Number: +32478509830
- Email: els.mehuys@ugent.be
-
Contact:
- Koen Boussery
- Phone Number: +3292648043
- Email: koen.boussery@ugent.be
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients presenting with a first prescription for one of the following drug classes: antihypertensive drugs (= low-ceiling diuretics, beta blocking agents (excl. non-selective beta-blocking agents), ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers), lipid-lowering drugs (= statins), antidiabetic drugs (= metformin, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose co-transporter 2 (SGLT2) inhibitors), or any combination thereof.
- Age 18 years or older
- Community-dwelling
Exclusion Criteria:
- The drug is prescribed for a non-cardiovascular indication (e.g. beta-blocking agent for migraine prophylaxis)
- Communication with the patient is not possible (e.g. due to cognitive impairment, insufficient knowledge of Dutch or French language)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control arm
Usual care
|
|
|
Experimental: Intervention arm
Community pharmacist intervention
|
The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NIH Patient Reported Outcomes Measurement Information System (PROMIS) Medication Adherence Scale (PMAS)
Time Frame: At 6 weeks and at 12 weeks follow-up
|
Patient-reported measure of medication adherence
|
At 6 weeks and at 12 weeks follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medication Possession Ratio (MPR)
Time Frame: Over 26 weeks post-baseline
|
Measure of medication adherence, using pharmacy refill records
|
Over 26 weeks post-baseline
|
|
Discontinuation rate
Time Frame: Over 26 weeks post-baseline
|
% of patients discontinuing the medication
|
Over 26 weeks post-baseline
|
|
Medication knowledge questionnaire
Time Frame: At 6 weeks and at 12 weeks follow-up
|
Questionnaire evaluating patient's basic knowledge about the medication
|
At 6 weeks and at 12 weeks follow-up
|
|
Beliefs about Medicines Questionnaire (BMQ-Specific)
Time Frame: At 6 weeks and at 12 weeks follow-up
|
Questionnaire evaluating patient's beliefs about the necessity of prescribed medication for controlling their illness (Specific-Necessity) and their concerns about the potential adverse consequences of taking it (Specific-Concerns)
|
At 6 weeks and at 12 weeks follow-up
|
|
Treatment response
Time Frame: At baseline and at 12 weeks follow-up
|
Systolic and diastolic blood pressure for patients starting an antihypertensive drug; lipid levels (total cholesterol, LDL and HDL) for patients starting a lipid-lowering drug; HbA1c for patients starting an antidiabetic drug
|
At baseline and at 12 weeks follow-up
|
|
Healthcare utilization
Time Frame: Over 12 weeks post-baseline
|
Number of general practitioner (GP) visits, specialist-physician visits, emergency department (ED) visits and hospital admissions
|
Over 12 weeks post-baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B6702023000469 - ONZ-2023-0360
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.